CCM
JAZZ icon

Cadian Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cadian Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100,000
Closed -$12.4M – 34
2018
Q4 		$12.4M Buy
+100,000
New +$14.8M 0.58% 25
2018
Q3 		– Sell
-725,092
Closed -$125M – 30
2018
Q2 		$125M Sell
725,092
-486,497
-40% -$79.5M 6.01% 6
2018
Q1 		$183M Sell
1,211,589
-73,600
-6% -$10.8M 9.88% 2
2017
Q4 		$173M Buy
1,285,189
+106,241
+9% +$14.7M 10.54% 3
2017
Q3 		$172M Sell
1,178,948
-213,627
-15% -$32.3M 8.07% 4
2017
Q2 		$217M Buy
1,392,575
+173,812
+14% +$26.6M 10.55% 1
2017
Q1 		$177M Sell
1,218,763
-322,019
-21% -$41.9M 8.46% 1
2016
Q4 		$168M Buy
1,540,782
+229,490
+18% +$25.6M 8.94% 1
2016
Q3 		$159M Buy
1,311,292
+547,056
+72% +$73.7M 8.4% 2
2016
Q2 		$108M Buy
764,236
+290,000
+61% +$42.8M 5.93% 6
2016
Q1 		$61.9M Sell
474,236
-54,580
-10% -$6.79M 4.16% 7
2015
Q4 		$74.3M Buy
528,816
+200,141
+61% +$27.7M 2.67% 13
2015
Q3 		$43.7M Buy
328,675
+153,675
+88% +$26.5M 1.57% 18
2015
Q2 		$30.8M Buy
175,000
+65,000
+59% +$11.7M 0.91% 29
2015
Q1 		$19M Buy
+110,000
New +$18.9M 0.51% 40

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Cadian Capital Management's JAZZ Position: Q1 2019 in Review

Cadian Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2019, closing a stake of 100,000 shares — an estimated $12.4M sold.

Cadian Capital Management first reported a position in JAZZ in Q1 2015 and held it in 15 quarters. The position peaked at $217M in Q2 2017. 427 funds tracked by Wall St. Rank hold JAZZ as of Q1 2019.

  • Cadian Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Cadian Capital Management sold 100,000 Jazz Pharmaceuticals shares in Q1 2019, an estimated $12.4M.
  • Cadian Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 15 quarters.
  • Cadian Capital Management's Jazz Pharmaceuticals position peaked at $217M in Q2 2017.
  • 427 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2019.

Based on Cadian Capital Management's 13F filing for Q1 2019, filed 14 May 2019.